Adult-Onset Still's Disease
New adult-onset Still's disease research, summarized each month in plain language.
2026 so far: So far in 2026 (January to September), real-world reports linked earlier or biologic-first IL-1 or IL-6 treatment with faster control and steroid reduction, alongside new MAS risk and AOSD activity scoring tools. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Biologics and steroid reduction. Observational data increasingly linked biologics with less steroid exposure.
- How MAS was treated. Reports clarified common MAS escalation patterns and relapse risk.
- Predicting MAS risk. Ferritin and systemic scoring repeatedly anchored MAS prediction models.
- Tracking AOSD activity. Multiple studies tested simpler, more responsive activity scores.
- Diagnosing AOSD sooner. Reports added tools and examples for difficult diagnoses.
New
September 2026
- MAS initial treatment. MAS care often began with high-dose steroids plus add-on drugs.
- MAS return after treatment. MAS sometimes came back after improvement, even with intensive care.
- AOSD activity scoring. Several scoring tools broadly matched clinician ratings of AOSD activity.
- Skin biopsy pattern. A specific skin-biopsy pattern appeared in many confirmed AOSD cases.
August 2026
- Canakinumab outcomes. Registries linked canakinumab to inactive disease in many children.
- Treatment sequence. Care often started with steroids, then moved to biologics.
- MAS risk scores. HScore separated MAS from non-MAS cases in one dataset.
July 2026
- First biologic treatment. Biologic-first treatment was linked to steadier remission in routine care.
- Stopping steroids. Stopping steroids was reported more often with biologic-first treatment.
- Lung involvement. Lung involvement was often symptom-free and linked to relapse.
- Fever diagnosis support. A record-based model helped flag AOSD when it was suspected.
June 2026
- Steroid-free control. Early biologic response was linked to later steroid-free inactive disease.
- Earlier canakinumab start. Starting canakinumab sooner was linked to faster steroid dose reduction.
- Relapse risk signs. High CRP and joint-dominant disease were linked to relapse.
May 2026
- IL-18 and inflammation. In one study, active IL-18 levels were higher and tended to move with other signs of inflammation in adult-onset Still’s disease.
- IL-18 test differences. IL-18 results varied widely across testing platforms, so the same sample could give different numbers in different labs.
- Complications over time. In a long-term cohort, some complications were reported over years of follow-up.
- Fever-only presentations. Some reported cases presented mainly as prolonged fever without the typical rash.
April 2026
- MAS risk markers. Higher ferritin levels and higher systemic disease scores were repeatedly linked with higher risk of macrophage activation syndrome (MAS).
- Combined risk scoring. Risk models estimated MAS risk more clearly when they combined several clinical and lab factors rather than using one lab test alone.
- Similar biologic responses. In one cohort, anakinra and tocilizumab showed similar response rates.
- Fungal infection signals. In one retrospective cohort, fungal infections were seen more often in people with broader organ involvement and higher immune activation markers.
March 2026
- Canakinumab follow-up signal. An early study goal was not met, but some later follow-up measures improved in a subset of people.
- Tocilizumab combination in practice. A real-world comparison linked tocilizumab add-on treatment with faster remission, but it cannot show that tocilizumab caused the difference.
- MAS risk score at admission. Five routine findings at hospital admission were used to sort people into higher versus lower in-hospital MAS risk groups.
- Simple activity checklist. A five-item set of symptoms plus CRP was used to label disease as active versus inactive.
February 2026
- Early remission with tocilizumab + steroids. A tocilizumab plus short-term high-dose steroid approach was linked to faster early remission, while longer-term differences were less clear and steroid stopping was reported more often over time.
- Escalation in severe MAS flares. In very severe, hard-to-control macrophage activation syndrome, some case reports described adding interferon-targeted or JAK-pathway medicines after steroids.
- Calprotectin as an MAS signal. Calprotectin was higher in macrophage activation syndrome and tended to move with ferritin, with mainly research evidence linking this pattern to interferon-alpha activity.
- Clues in atypical AOSD. In diagnostically challenging cases, very high ferritin was a repeated clue, and reports noted that the typical rash may be absent or not recognized.
January 2026
- Tocilizumab durability. Many stayed controlled and reduced steroid doses over time.
- Side effect reports. Some serious side effects occurred, and some people stopped treatment.
- Diagnosis symptom score. Higher symptom scores at diagnosis were linked to later complications.
Get the monthly update by email
Subscribe here to receive an email when a new monthly adult-onset Still's disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).